Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-0652-2021Class II

CryoValve SG Pulmonary Human Heart Valve. The valve is cryopreserved in a tissue culture medium containing...

Artivion, Inc. / initiated 2020-11-10 / Terminated / root cause: manufacturing process

CryoLife, Inc. began a recall of CryoValve SG Pulmonary Human Heart Valve. The valve is cryopreserved in a tissue culture medium containing cryoprotectants within the innermost pouch of a... on . FDA classified it as Class II and gives the reason as "On November 10, 2020, it was discovered that there are post- processing microbial culture test failures for other allografts, processed using a TRIS saline solution lot that was also used in processing allografts...". As of , the recall status on record is Terminated, and MDM tags the root cause as manufacturing process.

Recall record

Recall number
Z-0652-2021
Classification
Class II
Status
Terminated
Initiated
Posted
Terminated
Recalling firm
Artivion, Inc.
Product
CryoValve SG Pulmonary Human Heart Valve. The valve is cryopreserved in a tissue culture medium containing cryoprotectants within the innermost pouch of a three-pouch packaging system. The packaging system not only withstands ultracold temperatures, but also allows for aseptic introduction of the valve into the operating environment. Supercooling by liquid nitrogen boost is begun prior to crystallization to minimize ice crystal damage to the valve matrix. Finally, the valve is transferred to a liquid nitrogen freezer for long-term storage at or below 135C. CryoValve SG is distributed in two anatomic configurations: pulmonary valve and conduit, and pulmonary valve.
Product code
OHA Heart Valve, More Than Minimally Manipulated Allograft
Reason for recall
On November 10, 2020, it was discovered that there are post- processing microbial culture test failures for other allografts, processed using a TRIS saline solution lot that was also used in processing allografts subjected to the recall.
Root cause tag
manufacturing process
FDA root cause
Material/Component Contamination
Action
A Recall notification letter titled "Urgent - Voluntary Human Tissue Recall" was sent to consignees via email or hand delivered by firm representatives. On 11-Nov-2020, 4 letters were delivered to consignees. On 12-Nov-2020, 2 letters were delivered to consignees. The letter instructs the consignee to complete and return the enclosed postcard affirming that they received the notification. The affected product should be quarantined and returned to CryoLife immediately, if it has not been implanted. CryoLife Field Representatives were to provide information necessary to arrange for the return of the affected product. If the product has been implanted and the consignee has questions or requires clarification, the consignee is to contact Dr. Gregory Ray, CryloLife Medical Director at 800-438-8285.
Quantity in commerce
3 units
Distribution
Distributed nationwide to GA, AZ, TX, MO, and OK.
Product codes and lots
Model/Catalog Number: SGPV00 Serial Numbers: 11685214, 11685554, and 11682491 UDI: 00877234000447

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-0652-2021
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-0652-2021Class IITerminatedVoluntary: Firm initiated
Z-0653-2021Class IITerminatedVoluntary: Firm initiated